PMID- 32662255
OWN - NLM
STAT- MEDLINE
DCOM- 20210909
LR  - 20210909
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 44
IP  - 6
DP  - 2020 Dec
TI  - Serum Levels of Adipocyte Fatty Acid-Binding Protein Are Associated with Rapid 
      Renal Function Decline in Patients with Type 2 Diabetes Mellitus and Preserved 
      Renal Function.
PG  - 875-886
LID - 10.4093/dmj.2019.0221 [doi]
AB  - BACKGROUND: Recent studies have demonstrated that the levels of adipocyte fatty 
      acid-binding protein (A-FABP) are closely associated with diabetic kidney disease 
      (DKD) in patients with type 2 diabetes mellitus (T2DM). This study aimed to 
      examine the association between serum A-FABP level and rapid renal function 
      decline in patients with T2DM and preserved renal function. METHODS: This was a 
      prospective observational study of 452 patients with T2DM and preserved renal 
      function who had serial measurements of estimated glomerular filtration rate 
      (eGFR). Rapid renal function decline was defined as an eGFR decline of >4% per 
      year. The association between baseline serum A-FABP level and rapid renal 
      function decline was investigated. RESULTS: Over a median follow-up of 7 years, 
      82 participants (18.1%) experienced rapid renal function decline. Median A-FABP 
      levels were significantly higher in patients with rapid renal function decline, 
      compared to non-decliners (20.2 ng/mL vs. 17.2 ng/mL, P=0.005). A higher baseline 
      level of A-FABP was associated with a greater risk of developing rapid renal 
      function decline, independent of age, sex, duration of diabetes, body mass index, 
      systolic blood pressure, history of cardiovascular disease, baseline eGFR, urine 
      albumin creatinine ratio, total cholesterol, glycosylated hemoglobin, 
      high-sensitivity C-reactive protein and use of thiazolidinedione, insulin, 
      angiotensin-converting-enzyme inhibitors and angiotensin II-receptor blockers and 
      statin (odds ratio, 3.10; 95% confidence interval, 1.53 to 6.29; P=0.002). 
      CONCLUSION: A high level of serum A-FABP is associated with an increased risk of 
      rapid renal function decline in patients with T2DM and preserved renal function. 
      This suggests that A-FABP could play a role in the progression of DKD in the 
      early stages.
FAU - Seo, Da Hea
AU  - Seo DH
AD  - Department of Internal Medicine, Inha University School of Medicine, Incheon, 
      Korea.
FAU - Nam, Moonsuk
AU  - Nam M
AD  - Department of Internal Medicine, Inha University School of Medicine, Incheon, 
      Korea.
FAU - Jung, Mihye
AU  - Jung M
AD  - Department of Internal Medicine, Inha University School of Medicine, Incheon, 
      Korea.
FAU - Suh, Young Ju
AU  - Suh YJ
AD  - Department of Biomedical Sciences, Inha University School of Medicine, Incheon, 
      Korea.
FAU - Ahn, Seong Hee
AU  - Ahn SH
AD  - Department of Internal Medicine, Inha University School of Medicine, Incheon, 
      Korea.
FAU - Hong, Seongbin
AU  - Hong S
AD  - Department of Internal Medicine, Inha University School of Medicine, Incheon, 
      Korea.
FAU - Kim, So Hun
AU  - Kim SH
AD  - Department of Internal Medicine, Inha University School of Medicine, Incheon, 
      Korea.
LA  - eng
GR  - Inha/International
GR  - Inha University Hospital/International
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200710
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Fatty Acid-Binding Proteins)
SB  - IM
MH  - Adipocytes
MH  - Adult
MH  - Aged
MH  - Angiotensin Receptor Antagonists
MH  - Angiotensin-Converting Enzyme Inhibitors
MH  - *Diabetes Mellitus, Type 2
MH  - Disease Progression
MH  - Fatty Acid-Binding Proteins
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
PMC - PMC7801760
OTO - NOTNLM
OT  - Diabetes mellitus, type 2
OT  - Diabetic nephropathies
OT  - FABP4 protein, human
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2020/07/15 06:00
MHDA- 2021/09/10 06:00
PMCR- 2020/12/01
CRDT- 2020/07/15 06:00
PHST- 2019/11/19 00:00 [received]
PHST- 2020/01/08 00:00 [accepted]
PHST- 2020/07/15 06:00 [pubmed]
PHST- 2021/09/10 06:00 [medline]
PHST- 2020/07/15 06:00 [entrez]
PHST- 2020/12/01 00:00 [pmc-release]
AID - 44.e37 [pii]
AID - dmj-2019-0221 [pii]
AID - 10.4093/dmj.2019.0221 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2020 Dec;44(6):875-886. doi: 10.4093/dmj.2019.0221. Epub 2020 
      Jul 10.